Accessibility Menu
 
Immunovant logo

Immunovant

(NASDAQ) IMVT

Current Price$27.51
Market Cap$5.89B
Since IPO (2019)+191%
5 Year+77%
1 Year+97%
1 Month+0%

Immunovant Financials at a Glance

Market Cap

$5.89B

Revenue (TTM)

$0.00

Net Income (TTM)

$464.20M

EPS (TTM)

$-2.68

P/E Ratio

-10.80

Dividend

$0.00

Beta (Volatility)

1.15 (Average)

Price

$27.51

Volume

35,459

Open

$28.29

Previous Close

$27.51

Daily Range

$27.37 - $28.51

52-Week Range

$13.71 - $30.16

IMVT: Motley Fool Moneyball Superscore

61

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Immunovant

Industry

Biotechnology

Employees

362

CEO

Eric Venker, MD, PharmD

Headquarters

New York City, NY 10018, US

IMVT Financials

Key Financial Metrics (TTM)

Gross Margin

0%

Operating Margin

0%

Net Income Margin

0%

Return on Equity

-69%

Return on Capital

-49%

Return on Assets

-44%

Earnings Yield

-9.26%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$5.89B

Shares Outstanding

203.53M

Volume

35.46K

Avg. Volume

1.37M

Financials (TTM)

Gross Profit

$0.00

Operating Income

$438.15M

EBITDA

$437.77M

Operating Cash Flow

$375.87M

Capital Expenditure

$759.00K

Free Cash Flow

$376.63M

Cash & ST Invst.

$713.97M

Total Debt

$98.00K

Immunovant Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

$101.00K

N/A

Gross Margin

0.00%

N/A

Market Cap

$5.89B

N/A

Market Cap/Employee

$16.28M

N/A

Employees

362

N/A

Net Income

$110.64M

+0.4%

EBITDA

$108.98M

+4.6%

Quarterly Fundamentals

Name
Q3 2026YOY CHG

Net Cash

$994.52M

+165.4%

Accounts Receivable

$1.64M

-26.1%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

-100.0%

Return on Assets

-44.11%

N/A

Return on Invested Capital

-49.40%

N/A

Free Cash Flow

$92.33M

+8.2%

Operating Cash Flow

$92.33M

+8.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
KYMRKymera Therapeutics, Inc.
$82.21-2.71%
PRAXPraxis Precision Medicines, Inc.
$342.58-0.85%
AKROAkero Therapeutics, Inc.
$54.65+0.00%
NAMSNewAmsterdam Pharma Company N.V.
$35.44-3.90%

Trending Stocks

Symbol / CompanyPricePrice Chg
NOKNokia
$13.95-0.04%
FFord Motor Company
$13.40-0.07%
TQQQProShares Trust - ProShares UltraPro Qqq
$75.34-0.05%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$15.06-0.10%

Questions About IMVT

What is the current price of Immunovant?

Immunovant is trading at $27.51 per share.

What is the 52-week range for Immunovant?

Over the past 52 weeks, Immunovant has traded between $13.71 and $30.16.

How much debt does Immunovant have?

As of the most recent reporting period, Immunovant reported total debt of N/A.

How much cash does Immunovant have on hand?

Immunovant reported $994.52M in cash and cash equivalents in its most recent financial results.

What is Immunovant’s dividend yield?

Immunovant does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.